Pulse Biosciences (PLSE)
(Real Time Quote from BATS)
$15.91 USD
+1.05 (7.07%)
Updated Jul 11, 2024 01:24 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PLSE 15.91 +1.05(7.07%)
Will PLSE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PLSE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PLSE
Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Lags Revenue Estimates
Pulse Biosciences, Inc (PLSE) Reports Q1 Loss, Lags Revenue Estimates
PLSE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PLSE
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
Pulse Biosciences: Leadership Changes and Stockholder Decisions at Annual Meeting
Pulse Biosciences, Inc. Announces Commencement of Rights Offering